Recombinant IL22 (Fezakinumab Biosimilar) antibody

Catalog No. ABIN7581499

The Human Monoclonal anti-IL22 (Fezakinumab Biosimilar) antibody has been validated for ELISA, FACS, BLI, Func and SPR. It is suitable to detect IL22 (Fezakinumab Biosimilar) in samples from Human.

Quick Overview for Recombinant IL22 (Fezakinumab Biosimilar) antibody (ABIN7581499)

Target: IL22 (Fezakinumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This IL22 (Fezakinumab Biosimilar) antibody is un-conjugated

Application: ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-IL22 (Fezakinumab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-IL-22 Reference Antibody (fezakinumab)

Characteristics: Anti-IL-22 Reference Antibody (fezakinumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.

Purity: >95 %

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for IL22 (Fezakinumab Biosimilar)

Target: IL22 (Fezakinumab Biosimilar)

Alternative Name: IL-22 (Fezakinumab Biosimilar)

Target Type: Biosimilar

Molecular Weight: 145.5 kDa

UniProt: Q9GZX6